IP Library › Granted Patent US 12,697,352
Granted Patent B2
US 12,697,352 · App. 18/075,161 · Granted Aug 4, 2026

Instructions for composition and sensitivity

Inventors: Yair Alster (Tel Aviv, IL); Charles Bosworth (Las Vegas, NV); Hila Epstein-Barash (Shoham, IL); Omer Rafaeli (Udim, IL)
Assignee: Azura Ophthalmics Ltd.
A61K33/04A61K9/0048A61K9/06A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,352
App. No.
18/075,161
Filed
Dec 5, 2022
Granted
Aug 4, 2026
Kind
B2
Art Unit
1617
USPC
424/702
Abstract

Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS 2 ) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.

Claims (35)

1 . A method for treating a disease or disorder in or around an eye of an individual in need thereof, the method comprising:

administering a therapeutically effective amount of a pharmaceutical composition to an ocular surface, surrounding ocular tissues, or a combination thereof of the individual;

wherein the pharmaceutical composition comprises a therapeutically effective amount of selenium disulfide (SeS 2 ); and

wherein the pharmaceutical composition is administered at bedtime or within an hour of bedtime.

2 . The method of claim 1 , wherein the disease or disorder in or around the eye is dry eye syndrome.

3 . The method of claim 2 , wherein the individual has meibomian gland dysfunction (MGD).

4 . The method of claim 3 , wherein the pharmaceutical composition is administered at bedtime.

5 . The method of claim 4 , wherein the pharmaceutical composition is applied to an eyelid margin of the individual.

6 . The method of claim 5 , wherein the pharmaceutical composition is administered to the individual in a volume of less than about microliters (μL).

7 . The method of claim 1 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual.

8 . The method of claim 1 , wherein the pharmaceutical composition comprises selenium disulfide in a therapeutically effective concentration.

9 . The method of claim 8 , wherein the therapeutically effective concentration is about 0.5 by weight (wt. %).

10 . The method of claim 9 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual.

11 . The method of claim 10 , wherein the disease or disorder in or around the eye of the individual in need thereof is dry eye syndrome and the individual has MGD.

12 . The method of claim 1 , wherein the disease or disorder in or around the eye is meibomian gland dysfunction (MGD).

13 . The method of claim 1 , wherein the disease or disorder in or around the eye is meibomian gland dysfunction (MGD) and the individual has signs and symptoms of dry eye disease.

14 . The method of claim 13 , wherein the pharmaceutical composition is applied to an eyelid of the individual.

15 . The method of claim 14 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual at bedtime.

16 . The method of claim 15 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.

17 . The method of claim 1 , wherein the individual has signs and symptoms of dry eye disease.

18 . The method of claim 1 , wherein the individual has meibomian gland dysfunction (MGD).

19 . The method of claim 1 , wherein the individual has meibomian gland dysfunction (MGD) and sins and symptoms of dry eye disease.

20 . The method of claim 18 , wherein the pharmaceutical composition is applied to an eyelid of the individual.

21 . The method of claim 20 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to an eyelid margin of the individual at bedtime.

22 . The method of claim 18 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.

23 . The method of claim 1 , wherein the pharmaceutical composition is applied to an eyelid of the individual.

24 . The method of claim 23 , wherein the individual applies a volume of less than about 25 μL of the pharmaceutical composition to the eyelid of the individual.

25 . The method of claim 24 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.

26 . The method of claim 1 , wherein the pharmaceutical composition is administered to the individual in a volume of less than about 25 microliters (μL) at bedtime.

27 . The method of claim 26 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 wt. %.

28 . The method of claim 27 , wherein the individual applies the pharmaceutical composition to an eyelid margin of the individual.

29 . The method of claim 1 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 by weight (wt. %) to about 1.0% wt. %.

30 . The method of claim 29 , wherein the pharmaceutical composition comprises selenium disulfide in an amount of about 0.5 wt. %.

31 . The method of claim 30 , wherein the pharmaceutical composition the individual applies a volume of less than about 25 μL of the pharmaceutical composition.

32 . The method of claim 31 , wherein the pharmaceutical composition is applied to an eyelid margin of the individual at bedtime.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2022
From: ALSTER, YAIR; BOSWORTH, CHARLES; RAFAELI, OMER
To: AZURA OPHTHALMICS LTD.
Reel/Frame 062017/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2022
From: EPSTEIN-BARASH, HILA
To: AZURA OPHTHALMICS LTD.
Reel/Frame 062017/0585 →
Continuity (4)
Continuation 17471111 · Sep 9, 2021
Continuation PCTIB2021000005 · Jan 7, 2021
Provisional Application 62959738 · Jan 10, 2020
Related Publication 20230346832A1 · Nov 2, 2023
References Cited (400)
US 2209192A · Demsey · 1940 [cited by applicant]
US 3236730A · Galin · 1966 [cited by applicant]
US 3279466A · Mings · 1966 [cited by applicant]
US 3439674A · Lelicoff · 1969 [cited by applicant]
US 3934590A · Campagna et al. · 1976 [cited by applicant]
US 4002168A · Petterson · 1977 [cited by applicant]
US 4085750A · Bosshold · 1978 [cited by applicant]
US 4512977A · Lundy · 1985 [cited by applicant]
US 4531944A · Bechtle · 1985 [cited by applicant]
US 4543096A · Keene · 1985 [cited by applicant]
US 4605398A · Herrick · 1986 [cited by applicant]
US 4733802A · Sheldon · 1988 [cited by applicant]
US 4792334A · Py · 1988 [cited by applicant]
US 4834727A · Cope · 1989 [cited by applicant]
US 4838851A · Shabo · 1989 [cited by applicant]
US 4909801A · Casey et al. · 1990 [cited by applicant]
US 4946452A · Py · 1990 [cited by applicant]
US 4960407A · Cope · 1990 [cited by applicant]
US 4981479A · Py · 1991 [cited by applicant]
US 5007905A · Bauer · 1991 [cited by applicant]
US 5037406A · Smith et al. · 1991 [cited by applicant]
US 5059188A · Goddard · 1991 [cited by applicant]
US 5133702A · Py · 1992 [cited by applicant]
US 5221027A · Gibilsco · 1993 [cited by applicant]
US 5267986A · Py · 1993 [cited by applicant]
US 5330757A · Burke · 1994 [cited by applicant]
US 5366448A · Basilice et al. · 1994 [cited by applicant]
US 5382243A · Mulholland · 1995 [cited by applicant]
US 5387202A · Baron · 1995 [cited by applicant]
US 5401259A · Py · 1995 [cited by applicant]
US 5578019A · Feldman · 1996 [cited by applicant]
US 5645827A · Marlin et al. · 1997 [cited by applicant]
US 5810794A · Peplinski · 1998 [cited by applicant]
US 5922349A · Elliesen et al. · 1999 [cited by applicant]
US 6010488A · Deas · 2000 [cited by applicant]
US 6011067A · Hersh · 2000 [cited by applicant]
US 6033384A · Py · 2000 [cited by applicant]
US 6090086A · Bolden · 2000 [cited by applicant]
US 6153607A · Pflugfelder et al. · 2000 [cited by applicant]
US 6348508B1 · Denick, Jr. et al. · 2002 [cited by applicant]
US 6371945B1 · Sherman · 2002 [cited by applicant]
US 6495158B1 · Buseman et al. · 2002 [cited by applicant]
US 6508793B1 · Harrold · 2003 [cited by applicant]
US 6530908B1 · Sherman et al. · 2003 [cited by applicant]
US 7235065B1 · Sorensen · 2007 [cited by applicant]
US 7288259B2 · Sanders et al. · 2007 [cited by applicant]
US 7325708B2 · Barber · 2008 [cited by applicant]
US 7776915B2 · Morariu · 2010 [cited by applicant]
US 8206362B1 · Crosswell, Jr. · 2012 [cited by applicant]
US 8216195B2 · Wu · 2012 [cited by applicant]
US 8246589B2 · Marx · 2012 [cited by applicant]
US 8420699B1 · Dubow · 2013 [cited by applicant]
US 8449928B2 · Gilbard et al. · 2013 [cited by applicant]
US 8455016B2 · Maskin · 2013 [cited by applicant]
US 8734408B2 · Marx · 2014 [cited by applicant]
US 8853247B2 · Ren et al. · 2014 [cited by applicant]
US 9072581B1 · Alam et al. · 2015 [cited by applicant]
US 9205241B2 · McKay · 2015 [cited by applicant]
US 9463201B2 · Alster et al. · 2016 [cited by applicant]
US 10034887B2 · Alster et al. · 2018 [cited by applicant]
US 10213336B2 · Lorch et al. · 2019 [cited by applicant]
US 10299959B2 · Behan · 2019 [cited by applicant]
US 10383790B2 · Barkholt et al. · 2019 [cited by applicant]
US 10558915B2 · Gao et al. · 2020 [cited by applicant]
US 10588915B2 · Alster et al. · 2020 [cited by applicant]
US 10688122B2 · Amselem et al. · 2020 [cited by applicant]
US 10772889B2 · Johns et al. · 2020 [cited by applicant]
US 10772899B2 · Alster et al. · 2020 [cited by applicant]
US 11013749B2 · Alster et al. · 2021 [cited by applicant]
US 11040062B2 · Friedman et al. · 2021 [cited by applicant]
US 11103749B2 · Mermel et al. · 2021 [cited by applicant]
US 11324775B2 · Bosworth et al. · 2022 [cited by applicant]
US 11484516B2 · Amselem et al. · 2022 [cited by applicant]
US 11517386B2 · Luo et al. · 2022 [cited by applicant]
US 11517586B2 · Alster et al. · 2022 [cited by applicant]
US 11633410B2 · Alster et al. · 2023 [cited by applicant]
US 12048707B2 · Alster et al. · 2024 [cited by applicant]
US 12083147B2 · Bosworth et al. · 2024 [cited by applicant]
US 20020127256A1 · Murad · 2002 [cited by applicant]
US 20030180339A1 · Khaiat et al. · 2003 [cited by applicant]
US 20030224028A1 · Galey · 2003 [cited by applicant]
US 20030228299A1 · Droy-Lefaix et al. · 2003 [cited by applicant]
US 20040171561A1 · Popp · 2004 [cited by applicant]
US 20040192647A1 · Babizhayev · 2004 [cited by applicant]
US 20040220167A1 · Samiy · 2004 [cited by applicant]
US 20050065091A1 · Peyman · 2005 [cited by applicant]
US 20050101921A1 · Sherman · 2005 [cited by applicant]
US 20050124690A1 · Yoon et al. · 2005 [cited by applicant]
US 20050197614A1 · Pritchard et al. · 2005 [cited by applicant]
US 20060081726A1 · Gerondale · 2006 [cited by applicant]
US 20060110428A1 · Dejuan et al. · 2006 [cited by applicant]
US 20060129113A1 · Merrick · 2006 [cited by applicant]
US 20060157516A1 · Barber · 2006 [cited by applicant]
US 20060188471A1 · Podolsky et al. · 2006 [cited by applicant]
US 20060216251A1 · Morariu · 2006 [cited by applicant]
US 20070082017A1 · Tseng et al. · 2007 [cited by applicant]
US 20070104758A1 · Hamilton et al. · 2007 [cited by applicant]
US 20070166402A1 · Friedlaender et al. · 2007 [cited by applicant]
US 20070208181A1 · Lauener et al. · 2007 [cited by applicant]
US 20070269537A1 · Gupta · 2007 [cited by applicant]
US 20070280924A1 · Daniels et al. · 2007 [cited by applicant]
US 20070292355A1 · Tamarkin et al. · 2007 [cited by applicant]
US 20080020044A1 · Alam et al. · 2008 [cited by applicant]
US 20080025929A1 · Burton et al. · 2008 [cited by applicant]
US 20080081996A1 · Grenon et al. · 2008 [cited by applicant]
US 20080103376A1 · Felder · 2008 [cited by applicant]
US 20080114420A1 · Korb et al. · 2008 [cited by applicant]
US 20080242729A1 · Bollag · 2008 [cited by applicant]
US 20080318939A1 · Whitten · 2008 [cited by examiner]
US 20090061025A1 · Gao et al. · 2009 [cited by applicant]
US 20090123527A1 · Alam et al. · 2009 [cited by applicant]
US 20090214676A1 · Gao et al. · 2009 [cited by applicant]
US 20090238810A1 · Nyunt · 2009 [cited by applicant]
US 20090259204A1 · Galdeti et al. · 2009 [cited by applicant]
US 20090281508A1 · Alvino · 2009 [cited by applicant]
US 20100034870A1 · Sim et al. · 2010 [cited by applicant]
US 20100113338A1 · Watanabe et al. · 2010 [cited by applicant]
US 20100152201A1 · Riggs-Sauthier et al. · 2010 [cited by applicant]
US 20100204317A1 · Hunt et al. · 2010 [cited by applicant]
US 20100256552A1 · Korb et al. · 2010 [cited by applicant]
US 20100285155A1 · Gilbard et al. · 2010 [cited by applicant]
US 20110022010A1 · Grenon et al. · 2011 [cited by applicant]
US 20110059925A1 · Donnenfeld · 2011 [cited by applicant]
US 20110104206A1 · Nanduri et al. · 2011 [cited by applicant]
US 20110124725A1 · Maskin · 2011 [cited by applicant]
US 20110130729A1 · Korb et al. · 2011 [cited by applicant]
US 20110137214A1 · Korb et al. · 2011 [cited by applicant]
US 20110218241A1 · Preston et al. · 2011 [cited by applicant]
US 20110294897A1 · Aberg et al. · 2011 [cited by applicant]
US 20120016275A1 · Korb et al. · 2012 [cited by applicant]
US 20120028929A1 · Power et al. · 2012 [cited by applicant]
US 20120093876A1 · Ousler, III et al. · 2012 [cited by applicant]
US 20120128763A1 · Maskin · 2012 [cited by applicant]
US 20120150132A1 · Cress · 2012 [cited by applicant]
US 20120190661A1 · Trogden et al. · 2012 [cited by applicant]
US 20120226156A1 · Grenon et al. · 2012 [cited by applicant]
US 20120264681A1 · Braiman-Wiksman et al. · 2012 [cited by applicant]
US 20120288575A1 · Gilbard et al. · 2012 [cited by applicant]
US 20120310184A1 · Pedersen · 2012 [cited by applicant]
US 20130006202A1 · Marx · 2013 [cited by applicant]
US 20130053733A1 · Korb et al. · 2013 [cited by applicant]
US 20130064788A1 · Barnes et al. · 2013 [cited by applicant]
US 20130131171A1 · Maskin · 2013 [cited by applicant]
US 20130184242A1 · Eini et al. · 2013 [cited by applicant]
US 20130224272A1 · Gao et al. · 2013 [cited by applicant]
US 20130274214A1 · Brubaker · 2013 [cited by applicant]
US 20130280340A1 · Dobbie · 2013 [cited by applicant]
US 20130281390A1 · Brubaker · 2013 [cited by applicant]
US 20130303502A1 · Cavanagh et al. · 2013 [cited by applicant]
US 20130331768A1 · Nichamin · 2013 [cited by applicant]
US 20130344128A1 · Gao et al. · 2013 [cited by applicant]
US 20130345185A1 · Mitra et al. · 2013 [cited by applicant]
US 20140005171A1 · Aukunuru et al. · 2014 [cited by applicant]
US 20140010855A1 · Mahadevan et al. · 2014 [cited by applicant]
US 20140017886A1 · Teo et al. · 2014 [cited by applicant]
US 20140058340A1 · Guillon et al. · 2014 [cited by applicant]
US 20140142055A1 · Hosseini et al. · 2014 [cited by applicant]
US 20140142668A1 · Guillon et al. · 2014 [cited by applicant]
US 20140154333A1 · Moloney · 2014 [cited by applicant]
US 20140171884A1 · Rehkemper et al. · 2014 [cited by applicant]
US 20140171886A1 · Ogawa et al. · 2014 [cited by applicant]
US 20140206708A1 · Ren et al. · 2014 [cited by applicant]
US 20140350490A1 · Korodi · 2014 [cited by applicant]
US 20150025506A1 · Chau · 2015 [cited by applicant]
US 20150080349A1 · Blackwell et al. · 2015 [cited by applicant]
US 20150190279A1 · Acharya et al. · 2015 [cited by applicant]
US 20150265565A1 · O'Haimhirgin · 2015 [cited by applicant]
US 20150328044A1 · Coop et al. · 2015 [cited by applicant]
US 20150328290A1 · Leren et al. · 2015 [cited by applicant]
US 20160038339A1 · Behan · 2016 [cited by applicant]
US 20160106775A1 · Alster et al. · 2016 [cited by applicant]
US 20160199405A1 · Sutich · 2016 [cited by applicant]
US 20170035785A1 · Alster et al. · 2017 [cited by applicant]
US 20170087179A1 · Amselem et al. · 2017 [cited by applicant]
US 20170196732A1 · Marx · 2017 [cited by applicant]
US 20170224532A1 · Behan · 2017 [cited by applicant]
US 20170312364A1 · Bossy et al. · 2017 [cited by applicant]
US 20180043024A1 · Sakurai et al. · 2018 [cited by applicant]
US 20180177391A1 · Korb et al. · 2018 [cited by applicant]
US 20180250224A1 · Yamamoto et al. · 2018 [cited by applicant]
US 20180303906A1 · Caspi et al. · 2018 [cited by applicant]
US 20180318313A1 · Sengupta et al. · 2018 [cited by applicant]
US 20180344512A1 · Badawi · 2018 [cited by applicant]
US 20190167523A1 · Browka et al. · 2019 [cited by applicant]
US 20190183676A1 · Eaton et al. · 2019 [cited by applicant]
US 20190231788A1 · Godessart Marina et al. · 2019 [cited by applicant]
US 20190358083A1 · Barash · 2019 [cited by applicant]
US 20200179305A1 · Alster et al. · 2020 [cited by applicant]
US 20200179440A1 · Amselem et al. · 2020 [cited by applicant]
US 20200276048A1 · Hossain et al. · 2020 [cited by applicant]
US 20200330488A1 · Alster et al. · 2020 [cited by applicant]
US 20210161707A1 · Alster et al. · 2021 [cited by applicant]
US 20210236518A1 · Alster et al. · 2021 [cited by applicant]
US 20210330703A1 · Friedman et al. · 2021 [cited by applicant]
US 20210378863A1 · Gamboa Burgos · 2021 [cited by applicant]
US 20220226367A1 · Amselem et al. · 2022 [cited by applicant]
US 20220233350A1 · Van Gorden et al. · 2022 [cited by applicant]
US 20220233584A1 · Bosworth et al. · 2022 [cited by applicant]
US 20220305052A1 · Alster et al. · 2022 [cited by applicant]
US 20220323487A1 · Rafaeli et al. · 2022 [cited by applicant]
US 20220347207A1 · Epstein-Barash et al. · 2022 [cited by applicant]
US 20220388737A1 · Gamboa Burgos · 2022 [cited by applicant]
US 20220409657A1 · Alster et al. · 2022 [cited by applicant]
US 20230000675A1 · Alster et al. · 2023 [cited by applicant]
US 20230013824A1 · Alster et al. · 2023 [cited by applicant]
US 20230218642A1 · Alster et al. · 2023 [cited by applicant]
US 20240285679A1 · Bosworth et al. · 2024 [cited by applicant]
US 20240299445A1 · Friedman et al. · 2024 [cited by applicant]
CH 630801A5 · 1982 [cited by applicant]
CH 679912A5 · 1992 [cited by applicant]
CN 1093897A · 1994 [cited by applicant]
CN 101132693A · 2008 [cited by applicant]
CN 101418020A · 2009 [cited by applicant]
CN 101612161A · 2009 [cited by applicant]
CN 102038953A · 2011 [cited by applicant]
CN 103037802A · 2013 [cited by applicant]
CN 105439958A · 2016 [cited by applicant]
CN 105456287A · 2016 [cited by applicant]
CN 205459330U · 2016 [cited by applicant]
CN 106727285A · 2017 [cited by applicant]
CN 104936565B · 2017 [cited by applicant]
CN 109310665A · 2019 [cited by applicant]
CN 114989375A · 2022 [cited by applicant]
EP 0925799A2 · 1999 [cited by applicant]
EP 0930072A1 · 1999 [cited by applicant]
EP 1621191A1 · 2006 [cited by applicant]
EP 1915998A1 · 2008 [cited by applicant]
EP 2633852A1 · 2013 [cited by applicant]
EP 2664330A1 · 2013 [cited by applicant]
EP 2667877A2 · 2013 [cited by applicant]
EP 3206497A1 · 2017 [cited by applicant]
ES 283484U · 1985 [cited by applicant]
JP H069383A · 1994 [cited by applicant]
JP H07233057A · 1995 [cited by applicant]
JP H1171272A · 1999 [cited by applicant]
JP H11292793A · 1999 [cited by applicant]
JP 2010510961A · 2010 [cited by applicant]
JP 2010520210A · 2010 [cited by applicant]
JP 2013507132A · 2013 [cited by applicant]
JP 2014518275A · 2014 [cited by applicant]
JP 2015514722A · 2015 [cited by applicant]
JP 2016520335A · 2016 [cited by applicant]
JP 6501096B1 · 2019 [cited by applicant]
KR 19990063155A · 1999 [cited by applicant]
KR 101181302B1 · 2012 [cited by applicant]
NL 7804368A · 1979 [cited by applicant]
WO WO9611686A1 · 1996 [cited by applicant]
WO WO9724116A2 · 1997 [cited by applicant]
WO WO9824504A2 · 1998 [cited by applicant]
WO WO03035076A1 · 2003 [cited by applicant]
WO WO03050190A2 · 2003 [cited by applicant]
WO WO2005067892A1 · 2005 [cited by applicant]
WO WO2006137426A1 · 2006 [cited by applicant]
WO WO2007070463A2 · 2007 [cited by applicant]
WO WO2007113830A2 · 2007 [cited by applicant]
WO WO2007133703A2 · 2007 [cited by applicant]
WO WO2008027069A1 · 2008 [cited by applicant]
WO WO2008041177A2 · 2008 [cited by applicant]
WO WO2008068866A1 · 2008 [cited by applicant]
WO WO2008106228A2 · 2008 [cited by applicant]
WO WO2010006117A2 · 2010 [cited by applicant]
WO WO2011006079A2 · 2011 [cited by applicant]
WO WO2012092320A2 · 2012 [cited by applicant]
WO WO2012155062A1 · 2012 [cited by applicant]
WO WO2012161112A1 · 2012 [cited by applicant]
WO WO2013003731A2 · 2013 [cited by applicant]
WO WO2014078956A1 · 2014 [cited by applicant]
WO WO2014106759A1 · 2014 [cited by applicant]
WO WO2015017316A2 · 2015 [cited by applicant]
WO WO2015022546A1 · 2015 [cited by applicant]
WO WO2015054075A1 · 2015 [cited by applicant]
WO WO2015169728A1 · 2015 [cited by applicant]
WO WO2016063130A1 · 2016 [cited by applicant]
WO WO2016196989A1 · 2016 [cited by applicant]
WO WO2017055924A2 · 2017 [cited by applicant]
WO WO2017178892A2 · 2017 [cited by applicant]
WO WO2017182885A2 · 2017 [cited by applicant]
WO WO2018044758A1 · 2018 [cited by applicant]
WO WO2018178769A1 · 2018 [cited by applicant]
WO WO2020030975A2 · 2020 [cited by applicant]
WO WO2020208418A1 · 2020 [cited by applicant]
WO WO2020212760A2 · 2020 [cited by applicant]
WO WO2020247594A1 · 2020 [cited by applicant]
WO WO2021090058A2 · 2021 [cited by applicant]
WO WO2021090070A2 · 2021 [cited by applicant]
WO WO2021136968A2 · 2021 [cited by applicant]
WO WO2021140417A2 · 2021 [cited by applicant]
WO WO2021140419A1 · 2021 [cited by applicant]
WO WO2022084738A2 · 2022 [cited by applicant]
WO WO2022084739A1 · 2022 [cited by applicant]
WO WO2022084747A1 · 2022 [cited by applicant]
WO WO2022269348A1 · 2022 [cited by applicant]
WO WO2023043743A1 · 2023 [cited by applicant]
WO WO2023067387A2 · 2023 [cited by applicant]
WO WO2024100454A2 · 2024 [cited by applicant]
WO WO2024134266A1 · 2024 [cited by applicant]
WO WO2024134272A2 · 2024 [cited by applicant]
WO WO2025012700A2 · 2025 [cited by applicant]
WO WO2025012701A2 · 2025 [cited by applicant]
1.2.2 Congealing point. The International Pharmacopoeia 2019, retrieved from https://apps.who.int/phint/pdf/b/7.1.2.2.1.2.2-Congealing-point.pdf. [cited by applicant]
Aimsizer. 101-What is D90. Oct. 29, 2019 retrieved from http://www.aimsizer.com/faqs-what-is-d90.html. [cited by applicant]
Akyol-Salman et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 26(4):329-333 (2010). [cited by applicant]
Anonymous. Ointments and Types of ointment bases. Pharmaceutical Drugs and Dosage: Semisolid dosage forms. Available at https://www.pharmacy180.com/article/ointments-and-types-of-ointment-bases-2856/ (2019). [cited by applicant]
Bahn. The treatment of seborrheic blepharitis. South Med 47(8):749-53 (1954). [cited by applicant]
Barrault et al. Immortalized sebocytes can spontaneously differentiate into a sebaceous-like phenotype when cultured as a 3D epithelium. Exp Dermatol 21:299-319 (2012). [cited by applicant]
Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977). [cited by applicant]
Butovich et al. Human tear film and meibum. Very long chain wax esters and (O-acyl)-omega-hydroxy fatty acids of meibum. J Lipid Res 50(12):2471-2485 (2009). [cited by applicant]
Chalmers et al. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. Optom Vis Sci. 89:1435-1442 (2012). [cited by applicant]
Chalmers et al. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8): Use of an 8-Item Habitual Symptom Score to Reflect Change in Overall Opinion on Contact Lens Performance. Invest Ophthalmol Vis Sci 50:6337 (2009). [cited by applicant]
Chalmers et al. Cutoff score and responsiveness of the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8) in a Large daily disposable contact lens registry. Cont. Lens. Anterior Eye. 39(5):342-52 (2016). [cited by applicant]
Charlton et al. Topical urea as a treatment for non-infectious keratopathy. Acta Ophthalmol Scand 74(4):391-394 (1996). [cited by applicant]
Chew et al. An instrument for quantifying meibomian lipid on the lid margin: the Meibometer. Curr Eye Res 12(3):247-254 (1993). [cited by applicant]
Chougule et al. Synthesis, Characterization And Anthelmintic Activity Of Ivermectin Analogues Of Potent Nsaids. IAJPR 11(8):2035-2041 (2021). [cited by applicant]
Chowhan et al., Ophthalmic Preparations. Remington p. 541 (2012). [cited by applicant]
De Villiers. Chapter 23: Ointment Base. A Practical Guide to Contemporary Pharmacy Practice. Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins. Editors: Judith E. Thompson (pp. 277-290) (2009). [cited by applicant]
Driver et al. Meibomian Gland Dysfunction. Survey of Ophthalmology 40(5):343-367 (1996). [cited by applicant]
Efron et al. Lid Wiper Epitheliopathy. Prog Retin Eye Res. 53:140-174 (2016). [cited by applicant]
Foulks et al. The TFOS International Workshop on Contact Lens Discomfort: Report of the Subcommittee on Clinical Trial Design and Outcomes. Invest Ophthalmol Vis Sci 54:TFOS157-TFOS182 (2013). [cited by applicant]
Geerling et al., The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. The Association for Research in Vision and Ophthalmology… [cited by applicant]
Gonzalez-Hinojosa et al. Demodex and Rosacea: Is there a relationship? Ind. J Ophthalmol. 66(1):36-38 (2018). [cited by applicant]
Heiligenhaus et al. Therapy of dry eye disorders [Therapie von Benetzungsstorungen]. Klin Monatsbl Augenheilkd 204:162-168 (1994) (English Summary). [cited by applicant]
Higuchi et al. Selenium compound protects corneal epithelium against oxidative stress. PLoS One 7(9):e45612 (2012). [cited by applicant]
Itoh et al. The Molecular Mechanism of the Synthesis of the 21st Amino Acid, Selenocysteine. Journal of Japanese Crystal Society 56(3):186-193 (2014) (English Abstract). [cited by applicant]
Knop et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. IOVS 52(4):1938-1978 (2011). [cited by applicant]
Knop et al., The lid wiper and muco-cutaneous junction anatomy of the human eyelid margins: an in vivo confocal and histological study. Journal of Anatomy 218(4):449-461 (2011). [cited by applicant]
Koenig et al. Organic Sulfur Derivatives. V.2 Preparation and Properties of Some Long-Chain Mercapto Acids and Related Compounds. J Org Chem 23:1525-1530 (1958). [cited by applicant]
Korb et al. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc 51(3):243-251 (1980). [cited by applicant]
Lavyel. Selsunef ointment to treat squamous blepharitis. Am J Ophthalmol 49:820-821 (1960). [cited by applicant]
Lin et al. In vitro and in vivo percutaneous absorption of seleno-L-methionine, an antioxidant agent, and other selenium species. Acta Pharmacol Sin 32(9):1181-1190 (2011). [cited by applicant]
L-Selenomethionine—Safety Data Sheet. Cayman Chemical Revision Sep. 8, 2018. [cited by applicant]
Maskin. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea 29(10):1145-1152 (2010). [cited by applicant]
Millar et al. The effect of dietary and pharmacological manipulation of lipid production in the Meibomian and Harderian glands of the rabbit. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. Advances in Experimental … [cited by applicant]
Nagymihalyi et al. The influence of eyelid temperature on the delivery of Meibomian oil. Exp Eye Res 78:367-370 (2004). [cited by applicant]
Nederfors et al. Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. Eur J Oral Sci 103(6):351-354 ( Dec. 1995) (Abstract). [cited by applicant]
Nelson et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci. 52(4):1930-1937 (2011). [cited by applicant]
Nichols et al. Dual-Polymer Drops, Contact Lens Comfort, and Lid Wiper Epitheliopathy. Optom Vis Sci. 93(8):979-86 (2016). [cited by applicant]
Nichols et al. The Performance of the Contact Lens Dry Eye Questionnaire as a Screening Survey for Contact Lens-related Dry Eye. Cornea 21(5):469-475 (2002). [cited by applicant]
Nichols. The International Workshop on Meibomian Gland Dysfunction: Introduction. Invest Ophthalmol Vis Sci 52(4):1917-1921 (2011). [cited by applicant]
Omali et al. Quantification of individual proteins in silicone hydrogel contact lens deposits. Mol Vis. 19:390-399 (2013). [cited by applicant]
PCT/IB2015/02164 International Search Report and Written Opinion dated Mar. 29, 2016. [cited by applicant]
PCT/IB2017/000638 International Search Report and Written Opinion dated Oct. 30, 2017. [cited by applicant]
PCT/IB2017/00542 International Search Report and Written Opinion dated Sep. 21, 2017. [cited by applicant]
PCT/IB2018/000415 International Search Report and Written Opinion dated Aug. 30, 2018. [cited by applicant]
PCT/IB2019/000903 International Search Report and Written Opinion dated Feb. 27, 2020. [cited by applicant]
PCT/IB2019/000903 Invitation to Pay Additional Fees dated Dec. 31, 2019. [cited by applicant]
PCT/IB2020/000262 International Search Report and Written Opinion dated Aug. 12, 2020. [cited by applicant]
PCT/IB2020/000907 International Invitation to Pay Additional Fees dated May 5, 2021. [cited by applicant]
PCT/IB2020/001094 International Invitation to Pay Additional Fees dated May 5, 2021. [cited by applicant]
PCT/IB2020/00907 International Search Report and Written Opinion dated Jul. 21, 2021. [cited by applicant]
PCT/IB2020/00980 International Search Report and Written Opinion dated May 12, 2021. [cited by applicant]
PCT/IB2020/01094 International Search Report and Written Opinion dated Jul. 27, 2021. [cited by applicant]
PCT/IB2021/00005 International Invitation to Pay Additional Fees dated May 18, 2021. [cited by applicant]
PCT/IB2021/00005 International Search Report and Written Opinion dated Jul. 22, 2021. [cited by applicant]
PCT/IB2021/00007 International Search Report and Written Opinion dated May 25, 2021. [cited by applicant]
PCT/IB2022/000609 International Invitation to Pay Additional Fees dated Feb. 2, 2023. [cited by applicant]
PCT/IB2022/000609 International Search Report and Written Opinion dated Apr. 13, 2023. [cited by applicant]
PCT/IB2022/00343 International Search Report and Written Opinion dated Oct. 28, 2022. [cited by applicant]
PCT/US2016/01510 International Search Report and Written Opinion dated May 24, 2017. [cited by applicant]
Post et al. Demodex Folliculorum and Blepharitis Arch. Dermatol. 88(3):298-302 (1963). [cited by applicant]
PubChem substance SID 381577632 (2019). [cited by applicant]
Qiao et al. Emerging treatment options for meibomian gland dysfunction. Clinical Ophthalmology 7:1797-1803 (2013). [cited by applicant]
Rosenkrantz. Practical Applications of Topical Therapy for Allergic, Infectious, and Seborrheic Disorders. Clin. Tech. Small Anim. Pract. 21(3):106-116 (2006). [cited by applicant]
Rosenthal et al. effect of selenium sulfide on rabbit eyes. South Med J 55:318 (1962). [cited by applicant]
Schaumberg et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology Of, and Associated Risk Factors For, MGD. Invest. Ophthalmol. Vis. Sci. 52(4):1994-2005 (2011). [cited by applicant]
Schieving. The Seven Most Common Grades for Chemicals and Reagents. Nov. 2017 retrieved from https://www,labmanager.com/business-management/the-seven-most-common-grades-for-chemicals-and-reagents-2655. [cited by applicant]
Seifert et al. Immunocytochemical and ultrastructure evaluation of the distribution of nervous tissue and neuropeptides in meibomian gland. Graefe's Arch Clin Exp Ophthalmol 234:648-656 (1996). [cited by applicant]
Selenocysteine—American Chemical Society. Available at https://www.acs.org/content/acs/en/molecule-of-the-week/archive/s/selenocysteine.html (Jun. 24, 2019) (Retrieved Jul. 29, 2021). [cited by applicant]
Selenomethionine_ECHA website. Available at https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/notification-details/208470/961313 (Retrieved Jul. 29, 2021). [cited by applicant]
Sengupta et al., Selenoproteins are essential for proper keratinocyte function and skin development. PLoS One 5(8):e12249 (2010). [cited by applicant]
Siddireddy et al. Predictive Potential of Eyelids and Tear Film in Determining Symptoms in Contact Lens Wearers. Optom Vis Sci 95(11):1035-1045 (2018). [cited by applicant]
Srinivasan et al. Design of a Precision Medication Dispenser: Preventing Overdose by Increasing Accuracy and Precision of Dosage. IEEE Journal of Translational Engineering in Health and Medicine 6:1-6 (2018) (Art. No. 2… [cited by applicant]
Thygeson et al. Seborrheic blepharitis. Trans Am Ophthalmol Soc. 52:173-88 (1954-1955). [cited by applicant]
U.S. Appl. No. 14/732,622 Office Action dated Nov. 19, 2015. [cited by applicant]
U.S. Appl. No. 15/269,833 Office Action dated Aug. 7, 2017. [cited by applicant]
U.S. Appl. No. 15/269,833 Office Action dated Jan. 11, 2017. [cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Apr. 25, 2019. [cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Aug. 31, 2017. [cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Mar. 14, 2018. [cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Mar. 29, 2017. [cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Nov. 27, 2018. [cited by applicant]
U.S. Appl. No. 16/019,253 Office Action dated May 16, 2019. [cited by applicant]
U.S. Appl. No. 16/093,615 Office Action dated Dec. 22, 2020. [cited by applicant]
U.S. Appl. No. 16/093,615 Office Action dated Jul. 6, 2020. [cited by applicant]
U.S. Appl. No. 16/093,616 Office Action dated Dec. 7, 2020. [cited by applicant]
U.S. Appl. No. 16/093,616 Office Action dated May 7, 2021. [cited by applicant]
U.S. Appl. No. 16/093,616 Office Action dated Nov. 23, 2021. [cited by applicant]
U.S. Appl. No. 16/498,299 Office Action dated Mar. 16, 2022. [cited by applicant]
U.S. Appl. No. 16/498,299 Office Action dated May 4, 2021. [cited by applicant]
U.S. Appl. No. 16/498,299 Office Action dated Oct. 9, 2020. [cited by applicant]
U.S. Appl. No. 16/562,374 Office Action dated Oct. 30, 2019. [cited by applicant]
U.S. Appl. No. 16/919,749 Office Action dated Oct. 5, 2020. [cited by applicant]
U.S. Appl. No. 17/171,942 Office Action dated May 25, 2023. [cited by applicant]
U.S. Appl. No. 17/236,258 Office Action dated Oct. 18, 2022. [cited by applicant]
U.S. Appl. No. 17/357,749 Office Action dated Nov. 1, 2021. [cited by applicant]
U.S. Appl. No. 17/471,111 Office Action dated Mar. 31, 2022. [cited by applicant]
U.S. Appl. No. 17/471,111 Office Action dated Nov. 2, 2021. [cited by applicant]
U.S. Appl. No. 17/723,090 Office Action dated May 8, 2023. [cited by applicant]
U.S. Appl. No. 18/119,251 Office Action dated Jul. 6, 2023. [cited by applicant]
U.S. Appl. No. 16/795,497 Office Action dated Jul. 29, 2021. [cited by applicant]
Willis et al. Meibomian gland function, lid wiper epitheliopathy, and dry eye symptoms. Investigative Ophthalmology & Visual Science 52(14):3740-3740 (2011). [cited by applicant]